The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be

Study Name on
ClinicalTrials.gov (link is external)
A Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Mutation
Study Drug FDL169 and FDL176
Type of Study Drug CFTR modulation
Study Title A Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Mutation
Study Phase 1/2
Study Sponsor Flatley Discovery Lab LLC

Link on
clinicaltrials.gov (link is external)

https://clinicaltrials.gov/ct2/show/NCT03756922

Participating ECFS-CTN sites Please contact ecfs-ctn@uzleuven.be for most recent sitelist
Age 8 Years to 55 Years